» Articles » PMID: 16237069

Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially Versus Fully MHC-mismatched Cardiac Allografts

Overview
Journal J Immunol
Date 2005 Oct 21
PMID 16237069
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Although fully MHC-mismatched murine cardiac allografts are rapidly rejected, allografts mismatched at only MHC class I or class II alleles survive long term; the immunologic basis for the long-term survival of MHC class I- or II-mismatched allografts is unknown. We examined the roles of two recently described inhibitory receptors, B and T lymphocyte attenuator (BTLA) and programmed death-1 (PD-1), in the survival of partially or fully MHC-mismatched allografts using gene-deficient recipients as well as through use of blocking mAbs in wild-type hosts. Partially MHC-mismatched allografts showed strong induction of BTLA, but not PD-1 mRNA and survived long term in wild-type recipients, whereas targeting of BTLA or its ligand, herpesvirus entry mediator, but not PD-1, prompted their rapid rejection. By contrast, fully MHC-mismatched cardiac allografts were acutely rejected in wild-type recipients despite the induction of both BTLA and PD-1. Targeting of PD-1 in several fully MHC-mismatched models accelerated rejection, whereas targeting of BTLA unexpectedly enhanced PD-1 induction by alloreactive CD4 and CD8 T cells and prolonged allograft survival. In vitro studies using allogeneic dendritic cells and T cells showed that at low levels of T cell activation, BTLA expression was primarily induced, but that with increasing degrees of T cell activation, the expression of PD-1 was strongly up-regulated. These data suggest that BTLA and PD-1 exert distinct inhibitory actions in vivo, with the BTLA/herpesvirus entry mediator pathway appearing to dominate in regulating responses against a restricted degree of allogeneic mismatch.

Citing Articles

Internal regulation between constitutively expressed T cell co-inhibitory receptors BTLA and CD5 and tolerance in recent thymic emigrants.

Adegoke A, Thangavelu G, Chou T, Petersen M, Kakugawa K, May J Open Biol. 2024; 14(10):240178.

PMID: 39471840 PMC: 11521602. DOI: 10.1098/rsob.240178.


Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients.

Van Meerhaeghe T, Murakami N, Le Moine A, Brouard S, Sprangers B, Degauque N Clin Kidney J. 2024; 17(4):sfae061.

PMID: 38606169 PMC: 11008728. DOI: 10.1093/ckj/sfae061.


Immune Checkpoints in Solid Organ Transplantation.

Del Bello A, Treiner E Biology (Basel). 2023; 12(10).

PMID: 37887068 PMC: 10604300. DOI: 10.3390/biology12101358.


Roles of BTLA in Immunity and Immune Disorders.

Ning Z, Liu K, Xiong H Front Immunol. 2021; 12:654960.

PMID: 33859648 PMC: 8043046. DOI: 10.3389/fimmu.2021.654960.


Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.

Zhang H, Wang Z, Zhang J, Gui Z, Han Z, Tao J Front Immunol. 2021; 12:618737.

PMID: 33732243 PMC: 7959759. DOI: 10.3389/fimmu.2021.618737.